Company intelligence / Profile preview

Anavo Therapeutics

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Anavo Therapeutics is developing multiple first-in-class therapeutic programs targeting phosphatases, which were previously considered undruggable. The company is advancing its proprietary portfolio of programs toward clinical development.

Therapeutic areas: OtherOncology
Modalities: Small molecules (allosteric modulators)
Industry: Biotech

Partnerships

Planning to build partnerships around its platform to establish a pipeline across several indications

Beyond the preview

Go deeper on Anavo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anavo Therapeutics.

Explore the full profile